UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Mounjaro
DrugDrug Profile
Mounjaro is the brand name of tirzepatide, a dual GIP and GLP-1 receptor agonist for type 2 diabetes. It is used with diet and exercise to improve glycemic control and is administered as a once-weekly subcutaneous injection. The FDA first approved it on May 13, 2022.
- Drug Class
- Dual GIP receptor and GLP-1 receptor agonist
- Approval Status
- FDA approved; first approved May 13, 2022.
- Mechanism of Action
- Activates GIP and GLP-1 receptors, mimicking natural incretin hormone pathways.
- Mounjaro
- \Type 2 diabetes mellitus (adjunct to diet and exercise)\
Related News
Clinics Offer Semaglutide and Tirzepatide Weight Loss Programs
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Orforglipron Beats Oral Semaglutide in Type 2 Diabetes Trial; Hair Loss on GLP-1s Addressed
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
GLP-1 Drugs: Smell and Taste Risks, Soaring Poison Calls, and Reshaped Food Demand
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Lilly Amasses $1.5B Stockpile for Oral Obesity Drug as Logistics and Amylin Sectors Surge
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
UK Approves First GLP-1 Weight Loss Tablet as Semaglutide Landscape Shifts
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
FDA Proposes Limits on Compounding for GLP-1 Drugs as Safety Fears Grow
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
FDA Restricts Compounded GLP-1 Drugs as Weight-Loss Pill Race Heats Up
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Amgen Stock Slides 12.6% as Novo Nordisk Holds GLP-1 Lead
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
AstraZeneca Advances Oral GLP-1 Drug and Defends Diabetes Patent in Australia
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06734273 |
Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss |
RECRUITING | EARLY_PHASE1 |
| NCT06073184 |
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium |
NOT_YET_RECRUITING | PHASE2 |